Reportedly, Geron has decided to only focus on cancer research and for financial reasons has shut down its hESC trial for spinal cord injury.
This is a very sad day for stem cell science.
No more spinal cord injury patients will be treated in Geron’s former clinical trial.
This leaves Advanced Cell Technology as the only biotech conducting active clinical trials on hESC-based products. One has to wonder and worry about financial pressure on them as well.
Are stem cell-based clinical trials too expensive to make it all the way to the clinic?
What happens to the relationship between Geron and CIRM, which was going to give Geron substantial financial support?